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ABSTRACT 
Bone morphogenetic proteins (BMPs), in particular BMP-2, are the growth factors 
primarily responsible for osteoinduction. Knowledge of interactions between bone 
substitute materials and growth factor variants is crucial for designing bone 
substitutes with an ideal release profile. Here we compare glycosylated and non-
glycosylated recombinant human bone morphogenetic protein-2 (rhBMP-2) either 
incorporated into a hydrolyzable polyethylene glycol (PEG) hydrogel developed as a 
slow release system or adsorbed to a deproteinized bovine bone matrix (DBBM), a 
clinically well-established bone substitute material. rhBMP-2 loaded materials were 
immersed in cell culture medium and rhBMP-2 concentration profiles in the 
supernatant were determined by an enzyme-linked immunosorbent assay (ELISA). 
The corresponding biological activities were assessed in vitro by an alkaline 
phosphatase activity assay. We show a strong affinity of rhBMP-2 to DBBM and a 
reduced biological activity after its release from PEG hydrogels. Glycosylated 
rhBMP-2 was significantly less affected by hydrogels and interacted significantly 
stronger with DBBM than non-glycosylated rhBMP-2. We therefore question the 
combination of PEG hydrogels with DBBM as a rhBMP-2 delivery system over 
DBBM alone since rhBMP-2 released from the hydrogel will be trapped by DBBM. 
Moreover, our results suggest that glycosylated rhBMP-2 is favorable in combination 
with PEG hydrogels since its activity is better preserved. Whereas in combination 
with DBBM, non-glycosylated rhBMP-2 is favorable in order to benefit from an 
initially higher concentration of free rhBMP-2. 
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1 Introduction 
Bone has a unique capacity to heal itself without leaving a scar [1]. However, if a gap 
derived from an injury, disease or a surgical treatment reaches a critical size, the 
body is not able to repair the void on its own. For these critical-sized defects or when 
bone augmentation is required, a bone substitute is needed. The ideal material for a 
bone substitute provides a three-dimensional, mechanically stable structure, serves 
as a carrier for growth factors that enhance bone in-growth, contains living 
osteoblastic cells that are accepted by the body and should eventually be replaced 
by newly formed bone [2-4]. Autologous bone fulfills all of these criteria. 
Unfortunately, its use has severe drawbacks, namely increased morbidity at the 
harvest site and limited supply [5]. Therefore, alternatives such as allografts, 
xenografts or alloplasts are used. However, none of them provide all the properties 
of autografts [6]. 
Deproteinized bovine bone matrix (DBBM) is the gold standard off-the-shelf bone 
substitute material in dentistry [7]. It consists of the mineral phase of bovine bone, 
containing hydroxyapatite as the main component. DBBM is devoid of any organic 
material, therefore it is not as tough as natural bone and devoid of bone-inducing 
growth factors [8], making its combination with bone-inducing growth factors 
advantageous [9]. 
Bone morphogenetic proteins (BMPs), in particular BMP-2 and BMP-7, are the 
growth factors mainly responsible for osteoinduction [10]. They recruit and stimulate 
adult mesenchymal stem cells and preosteoblastic cells to migrate, proliferate and 
mature into osteoblasts [11, 12]. Currently, glycosylated Chinese hamster ovary 
(CHO)-expressed recombinant human BMP-2 (rhBMP-2) in combination with a 
collagen carrier (Infuse®, Medtronic Sofamor Danek, Memphis, Tennessee) is 
commercially available and approved by the Food and Drug Administration (FDA) 
and the European authorities for lumbar spine fusion and persisting long bone 
defects. Glycosylated rhBMP-2 is also approved for several dental applications [13]. 
Non-glycosylated rhBMP-2 produced by the prokaryotic expression system using E. 
coli, is an alternative that could substantially reduce production cost and the price for 
clinical application. Despite the fact that E. coli-derived proteins are non-
glycosylated, the biological potential of non-glycosylated rhBMP-2 has been reported 
to have bone-inducing activity similar to the glycosylated form [14-17]. In a human 
clinical trial, we demonstrated the efficacy of non-glycosylated rhBMP-2 in a bone 
augmentation procedure [9]. 
Controlling the release profile of rhBMP-2 from carrier materials is crucial to deliver 
the minimal effective growth factor load needed for bone reconstruction. Analysis of 
BMP expression during fracture healing revealed that BMP-2 expression was 
upregulated early and was elevated for up to 30 days [18]. It is therefore of 
advantage to release rhBMP-2 over a time period of days to weeks rather than hours 
[19]. Rapid diffusion away from the implantation site into body fluids, premature 
degradation of the carrier material, and inactivation of rhBMP-2 due to unwanted 
interactions with the carrier materials may limit the effectiveness of rhBMP-2 [19-24].  
An approach for a system composed of clinically evaluated materials that provides 
mechanical stability and allows sustained growth factor delivery is the combination of 
DBBM with hydrolysable polyethylene glycol (PEG) hydrogels [25-30]. In such a 
system, the release profile of the growth factor is dependent on the physical binding 
strength to the hydrogel, the degradation characteristics of the hydrogel and the 
interaction of the applied growth factor with the DBBM. A tunable, hydrolysable PEG 
hydrogel system based on a Michael-type reaction between PEG chains 
functionalized with acrylate groups and thiol groups has been previously developed 
[31]. The PEG system has been evaluated in clinical studies [32] and it was recently 
demonstrated that improved bone formation can be achieved by entrapping rhBMP-2 
as well as parathyroid hormone peptide in this hydrolysable synthetic matrix [25, 30].  
Considering the similar bioactivity of glycosylated and non-glycosylated rhBMP-2, 
understanding the differences in the release characteristics of these variants from 
the carrier materials and the effect of their interaction with the carrier materials on 
their bioactivity is crucial. This analysis would enable the development of a 
successful composite of these well-known materials that allows faster bone 
formation and more economical use of growth factors. We therefore investigated the 
differences between glycosylated and non-glycosylated rhBMP-2 in terms of their 
interactions with DBBM, hydrolysable PEG hydrogels, and the combination of these 
materials as well as the bioactivity of the released rhBMP-2 variants.  
2 Materials and Methods 
2.1 General Preparations 
Non-glycosylated rhBMP-2 was expressed in E.coli and refolded as previously 
described [33]. Glycosylated rhBMP-2 was obtained from Genetics Institute Inc., 
Massachusetts, USA. Both rhBMP-2 variants were desalted by solvent exchange to 
1 mM HCl using centrifugal filters (MWCO 10 kDa, Millipore, Zug, Switzerland). 
rhBMP-2 solutions were sterilized using Millex-LG Sterilizing Filter Units (0.2 m, 
Millipore, Zug, Switzerland). The concentration of rhBMP-2 was determined by a 
Bradford assay (Thermo Fisher Scientific, Lausanne, Switzerland) and samples were 
diluted in 1 mM HCl to 1 µg/µl accordingly. 
All following experiments were carried out under sterile conditions and all materials 
were sterilized by vapour sterilization (134 °C) in the central sterilization facilities of 
the University Hospital Zurich unless specified separately. All experiments were 
carried out at room temperature (room temperature varied between 20 and 25 °C) 
unless specified separately. All samples were prepared with both glycosylated and 
non-glycosylated rhBMP-2. 
2.2 Preparation of Bone Substitute Components 
Hydrolyzable mPEG hydrogels were formed by a Michael-type reaction between 
acrylate and thiol groups described earlier by Elbert, et al. [31] and prepared similarly 
to previous in vivo studies [25, 30]. 15 kDa 4arm PEG functionalized with an acrylate 
group at the end of each arm and 3.8 kDa linear PEG dithiol dissolved in 1 mM HCl 
and gamma-sterilized were kindly provided by the Institute Straumann AG (Basel, 
Switzerland). Briefly, 50 µl PEG gels (unreacted volume) were formed in low binding 
microcentrifuge tubes (Eppendorf, Basel, Switzerland) in the presence or absence of 
2.5 µg rhBMP-2 and/or 25 mg of DBBM (Bio Oss®, small spongiosa granules 0.25 – 
1 mm, gamma-sterilized, kindly provided by Geistlich Biomaterials, Wollhusen, 
Switzerland) by mixing acrylate and thiol PEGs in a 0.1 M triethanolamine solution. 
The volume of mPEG hydrogel was chosen to exactly cover the volume of the loose 
DBBM particles allowing a homogeneous distribution of DBBM in the hydrogel. The 
gelation reaction was allowed to take place for 30 min. In order to shorten the time 
periods for this study, the precursors were chosen for a final concentration of 3% 
(w/v) PEG allowing the mPEG hydrogel to hydrolyze completely after 3 days. 
In order to adsorb rhBMP-2 to DBBM from solution, 25 mg of DBBM were mixed with 
50 µl 1 mM HCl containing 2.5 µg rhBMP-2. The mixture was vortexed, briefly spun 
down (10600xg, 10s) in a centrifuge and incubated for 60 min. Samples were used 
immediately without removing the liquid from the adsorption procedure. For the 
adsorption of rhBMP-2 to DBBM via lyophilisation, 25 mg of DBBM were mixed with 
50 µl 1 mM HCl containing 2.5 µg rhBMP-2. The mixture was vortexed, briefly spun 
down in a centrifuge (10600xg, 10s) and frozen immediately using liquid nitrogen. 
Frozen samples were lyophilized overnight. Controls were prepared without the 
addition of rhBMP-2. The pH change of 1 mM HCl solution 1h after the immersion of 
DBBM was evaluated using the same ratio between DBBM and 1 mM HCl as for the 
sample preparation. 
2.3 Determination of rhBMP-2 Concentration Profiles 
rhBM2-loaded samples and according controls were immersed in cell culture 
medium (Dulbecco’s Modified Eagle Medium (D-MEM, Invitrogen, Basel, 
Switzerland) containing 10% inactivated fetal bovine serum (FBS, Invitrogen), 2 mM 
L-Glutamine (Invitrogen), 20 mM HEPES (stock adjusted to pH 7.4, SigmaAldrich, 
Buchs, Switzerland), 100 U/ml Penicillin and 100 g/ml Streptomycin 
(Penicillin/Streptomycin, Invitrogen)) resulting in a final volume of 500 l. The final 
sample volume was calculated including the hydrolyzable mPEG hydrogel 
(unreacted volume) as well as the liquid remaining in DBBM samples and controls 
but excluding the non-degradable (non-degradable regarding this time span) volume 
of DBBM. After preincubation for one hour in cell culture medium to allow initial 
adsorption of serum proteins, 2.5 µg of rhBMP-2 were added to the controls. Positive 
controls of 500 l cell culture medium containing 2.5 g rhBMP-2 were prepared. 
Thus, all samples, controls and the positive controls contained 2.5 µg rhBMP-2. 
Empty controls were prepared without the addition of rhBMP-2. An overview of all 
samples and controls as well as their abbreviations is shown in      
 
Figure 1. All samples and controls were incubated at 37 °C for 15 days. 50 µl 
supernatant were taken after 1h, 1, 2, 3, 6, 9 and 15 days of incubation and replaced 
by 50 µl of fresh cell culture medium. The removed supernatant aliquots were stored 
at -20 °C for later analysis.  
The concentration of rhBMP-2 in the supernatant was determined by an enzyme-
linked immunosorbent assay (ELISA) against rhBMP-2 (R&D Systems, Quantikine 
BMP-2, Abingdon, UK). Standard series of glycosylated and non-glycosylated 
rhBMP-2 were prepared to determine the rhBMP-2 concentration in the samples. 
The cumulative amount of released rhBMP-2 was calculated taking into account the 
removal and addition of 50 µl of fresh medium at each time point. All results were 
standardized to the positive controls (100%). 
2.4 Cell Culture Assays 
2.4.1 Cell Stimulation 
Glycosylated and non-glycosylated rhBMP-2 were tested for differences in their 
biological activity as well as for differences in their stability at 37 °C in vitro. Standard 
series (100 - 1000 ng/ml) of both rhBMP-2 variants were prepared in cell culture 
medium. The stability in cell culture medium was determined by incubating rhBMP-2 
at 37 °C in cell culture medium for 0, 3, 9, 15 and 30 days without cells. A 
premyoblastic cell line (C2C12, ATCC, Molsheim Cedex, France) was stimulated 
with the standard series and the samples prepared for the stability test and tested for 
alkaline phosphatase activity as described in section  2.4.3. 
The biological activity of the rhBMP-2 variants released from bone substitute 
materials as described in section  2.3 as well as the impact of bone substitute 
material degradation products and growth factors on cell viability were tested by 
stimulating C2C12 cells. Cells were stimulated with cell culture medium supernatant 
from a 15 days release from bone substitute materials prepared as described in 
section  2.3. Stimulated cells were tested for their viability as described in section 
 2.4.2 and for their ALP activity as described in section  2.4.3.  
2.4.2 Cell Viability 
Cell viability was evaluated after 3 and 6 days of incubation at 37 °C and 5% CO2 in 
a humidified atmosphere. Viability was determined by adding cell proliferation 
reagent WST-1 (Roche, Basel, Switzerland) to the cell culture medium at the 
concentration specified by the manufacturer. Cells were incubated in presence of the 
cell proliferation reagent for 45 min at 37 °C and 5 % CO2. The resulting colour 
reaction was evaluated by measuring the optical density at 450 nm using a plate 
reader (Synergy HT, Biotek, Luzern, Switzerland). 
2.4.3 Alkaline Phosphatase Activity 
The biological activity of rhBMP-2 was determined via an assay for alkaline 
phosphatase (ALP) activity, an early marker for osteoblastic differentiation. ALP is 
expressed by mesenchymal progenitor cells exposed to rhBMP-2 and its activity 
therefore provides an appropriate functional assessment of the growth factors 
bioactivity [34]. In detail, C2C12 cells were stimulated for 6 days at 37 °C and 5 % 
CO2 and were subsequently lysed using 0.56 M 2-Amino-2-methyl-1-propanol 
(SigmaAldrich, Buchs, Switzerland) (pH, 10 containing 0.2 % Triton X-100 
(SigmaAldrich)). ALP activity in the lysis buffer was determined via the kinetics of a 
colour reaction based on the reduction of p-nitrophenyl phosphate (Sigma Aldrich) to 
p-nitrophenol. The DNA concentration of the lysate was determined using a 
PicoGreen assay (Invitrogen, Basel, Switzerland). Optical density of the p-
nitrophenol reaction (410 nm) and fluorescence of PicoGreen (ex = 480 nm, em = 
520 nm) was detected with a plate reader (Synergy HT, Biotek, Luzern, Switzerland). 
The determined ALP activity was adjusted to the total cell number by standardizing it 
to the DNA concentration. All results were standardized to the positive controls 
(100%). 
2.5 Statistical Analysis 
All experiments were carried out with a total number of 6 individual and independent 
samples for each condition (n=6), except for the ALP assay which was carried out 
with 12 independent samples (n=12). Each experiment was carried out twice. 
Gaussian distribution of samples was confirmed by a Shapiro-Wilk test. A two-tailed, 
heteroscedastic t-test (P<0.05) was applied to determine whether or not there are 
statistically significant differences between concentrations and/or activity of 
glycosylated and non-glycosylated rhBMP-2 after 15 days of incubation. For the 
statistical analysis of the cell culture viability, repeated measures ANOVA and 
subsequent pairwise Student’s t-test with corrected P-values according to Bonferroni 
were used to detect significant differences between samples devoid of growth 
factors, loaded with non-glycosylated or glycosylated rhBMP-2. 
3 Results 
3.1 Interaction of rhBMP-2 with mPEG Hydrogels 
Cumulative concentration of both glycosylated and non-glycosylated rhBMP-2 in the 
cell culture medium supernatant of mPEG hydrogel samples was measured by an 
ELISA. The concentration of both growth factor variants increased up to day 3 and 
subsequently remained constant up to day 15 (                     
 
Figure 2). However, only part of the initial amount of rhBMP-2 was detected after 15 
days of incubation time. We found significant differences between the concentration 
of glycosylated (56 ± 4% of positive control) and non-glycosylated (26 ± 2% of 
positive control) rhBMP-2 at day 15. A comparison of the mPEG hydrogel controls 
showed reduced concentrations of both rhBMP-2 variants. There was no significant 
change in concentration during the incubation time and there was no significant 
difference between the concentration of glycosylated (58 ± 11% of positive control) 
and non-glycosylated (56 ± 5% of positive control) rhBMP-2 at day 15 for the mPEG 
controls. 
3.2 Interaction of rhBMP-2 with DBBM 
pH measurements showed that the pH of 1 mM HCl was neutralized by DBBM after 
1h if mixed at a concentration of 500 mg/ml DBBM (data not shown). We did not find 
any significant difference in adsorption behavior of rhBMP-2 between immersion in 1 
mM HCl containing rhBMP-2 and lyophilisation (data not shown). We therefore 
applied the adsorption procedure without lyophilization for loading DBBM with 
rhBMP-2. After 1h adsorption in 1 mM HCl and 1h incubation in cell culture medium, 
30 ± 14% glycosylated rhBMP-2 and 32 ± 4% non-glycosylated rhBMP-2 were 
detected in the cell culture medium supernatant relative to the positive control. These 
levels dropped to 7 ± 3% glycosylated and 16 ± 7% non-glycosylated rhBMP-2 after 
15 days, showing a significant difference between the two growth factor variants 
(
 
Figure 3 A). Concentrations of rhBMP-2 variants in the cell culture medium 
supernatant of DBBM controls showed a higher initial concentration than in the 
samples 
( 
Figure 3 A & B). By day 3 of incubation the concentrations in the supernatant of the 
controls dropped to similar levels to the concentrations in the supernatant of the 
samples showing significant differences in concentration between glycosylated (7 ± 
2% of positive control) and non-glycosylated (19 ± 3% of positive control) rhBMP-2 
after 15 days.  
3.3 Combination of mPEG hydrogel, DBBM and rhBMP-2 
We detected strongly reduced concentrations of glycosylated and non-glycosylated 
rhBMP-2 in the cell culture medium supernatant of DBBM in mPEG samples 
compared to the positive controls 
(
 
Figure 4 A). A maximum of 17 ± 3% glycosylated and 5 ± 4% non-glycosylated 
rhBMP-2 was detected after 6 days. After 15 days we found significant differences 
between the concentration of glycosylated (11 ± 3%) and non-glycosylated (3 ± 2%) 
rhBMP-2. A high initial concentration of rhBMP-2 was found in the cell culture 
medium supernatant of the controls 
(
 
Figure 4 B). After 3 days we observed a quick drop of both the concentration of 
glycosylated and non-glycosylated rhBMP-2. After 15 days of incubation the 
concentration was found to be significantly higher for the non-glycosylated (13 ± 4% 
of positive control) than for the glycosylated (5 ± 4% of positive control) rhBMP-2. 
3.4 Cell Viability - Influence of Degradation Products and rhBMP-2 
C2C12 cells stimulated with the cell culture medium supernatant from all samples 
were tested for their cell viability. After three days, we found a significantly elevated 
cell viability comparing controls devoid of rhBMP-2 and samples with glycosylated 
rhBMP-2 in the positive controls and the DBBM sample group 
( 
Figure 5 A). After 6 days, cell viability was significantly elevated in samples 
containing either glycosylated or non-glycosylated rhBMP-2 in the sample groups of 
positive controls, mPEG hydrogel and DBBM in mPEG hydrogel. There were no 
significant differences between samples containing glycosylated and non-
glycosylated rhBMP-2 
(
 
Figure 5 B). Comparing the cell viability between the bone substitute materials, we 
did not find any significant differences. 
Along with the measurement of the biological activity of rhBMP-2 (section  2.4), we 
determined the total amount of DNA of the stimulated cells by a PicoGreen assay. 
After 6 days we found a significantly higher amount of DNA in samples containing 
glycosylated or non-glycosylated rhBMP-2, however we did not find any significant 
differences between samples containing glycosylated or non-glycosylated rhBMP-2 ( 
 
Figure 6). However, comparing the DNA content between samples stimulated with 
cell culture supernatant from bone substitute materials not containing rhBMP-2, we 
found a significant decrease for those samples containing mPEG hydrogels. 
3.5 Biological Activity of rhBMP-2 – Impact of Bone Substitute Materials 
The biological activity of glycosylated and non-glycosylated rhBMP-2 was tested by 
stimulating C2C12 cells with various concentrations of both growth variants and 
testing them for their ALP activity. We did not find any significant differences 
between glycosylated and non-glycosylated rhBMP-2 
(
 
Figure 7 A). We found a strong decrease in ALP activity when stimulating C2C12 
cells with rhBMP-2 preincubated for various times in cell culture medium at 37 °C 
and 5% CO2 
(
 
Figure 7 B). Glycosylated (28 ± 2% initial activity) rhBMP-2 was significantly more 
affected than non-glycosylated (40 ± 3% initial activity) rhBMP-2 after 30 days of 
preincubation. 
The impact of incubating rhBMP-2 together with bone substitute materials on the 
bioactivity of the growth factor was investigated by stimulating C2C12 cells with the 
cell culture supernatant from mPEG hydrogels, DBBM and DBBM in mPEG hydrogel 
and testing them for their ALP activity. Incorporation into mPEG hydrogels reduced 
the activity of rhBMP-2 in the cell culture medium supernatant. The activity of non-
glycosylated rhBMP-2 (49 ± 6% of positive control) was reduced significantly more 
than the activity of the glycosylated rhBMP-2 (66 ± 17% of positive control) (                      
 
Figure 8). The activity of rhBMP-2 in the cell culture medium supernatant of DBBM 
was strongly decreased. This decrease was significantly higher for glycosylated (9 ± 
4% activity of positive control) than for non-glycosylated rhBMP-2 (25 ± 8% activity of 
positive control) (                             
Figure 8). The activity of rhBMP-2 released from mPEG hydrogels having DBBM and 
rhBMP-2 incorporated was strongly decreased as well. The decrease was 
significantly higher for non-glycosylated (9 ± 3% activity of positive control) than it 
was for glycosylated rhBMP-2 (18 ± 3% activity of positive control) (                      
 
Figure 8). 
4 Discussion 
Our aim was to understand the differences between the interaction of glycosylated 
and non-glycosylated rhBMP-2 with clinically evaluated bone substitute materials. 
This analysis should ultimately allow for a combination of known materials and 
growth factors leading to an improved bone reconstruction. For our investigation we 
chose two well evaluated materials, mPEG hydrogels and DBBM. Both materials 
have previously been clinically tested for bone augmentation procedures in dentistry 
[7, 9, 25-30, 32].  
We evaluated the equivalence of the two variants of rhBMP-2. In agreement with 
literature [9, 14-17], we found the biological activity of the glycosylated and non-
glycosylated rhBMP-2 to be alike in vitro 
(
 
Figure 7). The biological activity of both variants drops rapidly in cell culture medium 
at 37 °C. This activity decrease has to be considered for rhBMP-2 delivery in vivo as 
well as for experimental design in vitro. Therefore, we compared all of our samples 
to a positive control of rhBMP-2 in cell culture medium. We further investigated 
equivalence of cell viability stimulated by the two variants of rhBMP-2. We observed 
a trend for an increase in cell viability in the presence of cell culture medium 
supernatant from preincubated bone substitute materials and/or glycosylated or non-
glycosylated rhBMP-2 after 3 days and found a significant increase after 6 days 
(
 
Figure 5 A & B). This increase in viability is reflected in the significantly higher total 
amount of DNA per sample in those samples containing rhBMP-2 ( 
 
Figure 6) Our results agree with other work that shows the stimulation of cell viability 
by both glycosylated and non-glycosylated rhBMP-2 [17]. 
In investigating the effects of the mPEG hydrogel on the rhBMP-2 variants, we found 
that incorporating rhBMP-2 into an mPEG hydrogel reduces the amount of growth 
factor detected in the cell culture medium supernatant (                     
 
Figure 2) as well as the amount of active rhBMP-2 detected (                      
 
Figure 8) in the supernatant after 15 days of incubation. We hypothesize that this 
reduction is mainly caused by an interaction of rhBMP-2 with the PEG starting 
materials during gel formation. The thiol groups on the linear PEGs could attack the 
disulfide bonds of the rhBMP-2 dimers, leading to formation of monomers, incorrectly 
refolded dimers or even covalent incorporation of monomers into the mPEG hydrogel 
network. This hypothesis is supported by the significantly lower decrease in 
concentration of the glycosylated rhBMP-2, since the glycosylation can provide a 
protective effect. It is further supported by the fact that the concentration of non-
glycosylated rhBMP-2 in the supernatant of the controls, where rhBMP-2 is added 
after mPEG hydrogel formation, is much higher than in the supernatant of the 
corresponding control. However, it is possible that a weaker physical interaction 
between rhBMP-2 and remnants of the degraded mPEG hydrogel might be 
responsible for the reduced detection of rhBMP-2 in the controls. Although controlled 
PEGylation offers a great possibility to increase solubility and half-life of BMP-2 [35] 
or even allows for enzymatically controlled growth factor release [36] it should be 
avoided in order to deliver functional native rhBMP-2. Therefore, if applied together 
with an mPEG hydrogel, glycosylated rhBMP-2 is superior. 
In contrast to the samples containing mPEG hydrogel, only a small part of the initial 
rhBMP-2 concentration can be detected in the cell culture medium supernatant of 
DBBM samples after 15 days of immersion. The amount of active rhBMP-2 detected 
in the cell culture medium supernatant is reduced to a corresponding amount. We 
attribute this effect to the high affinity of BMP-2 to hydroxyapatite-based materials 
[37] as well as to the high surface area (79.7 m2/g) of DBBM due to its micro- and 
nano-structure [38]. Moreover, instead of the expected release after immersion of 
DBBM preloaded with rhBMP-2, adsorption of rhBMP-2 continued even in the 
presence of serum proteins from the cell culture medium 
(
 
Figure 3 A). This result agrees with other work showing that the affinity of rhBMP-2 
to hydroxyapatite is higher than the affinity of bovine serum albumin to 
hydroxyapatite [37]. The reduced activity of the supernatant, however, does not 
necessarily imply a reduced activity in vivo, as indicated by successful studies on the 
combination of DBBM and rhBMP-2 [9, 32, 39]. rhBMP-2 could be adsorbed to 
DBBM in an active or a denatured form, or it could be that it is reactivated upon 
release after the slow degradation of DBBM in vivo. The significantly stronger affinity 
of glycosylated rhBMP-2 to DBBM compared to the non-glycosylated variant seems 
to recommend the use of glycosylated rhBMP-2 if applied together with DBBM. 
However, Brown et al. have shown in vivo that an initially high concentration of 
rhBMP-2 followed by a slow release is favourable over a slow release only [19]. This 
fact together with the much lower production costs for the expression of rhBMP-2 in 
E.coli makes non-glycosylated rhBMP-2 the preferred protein if applied together with 
DBBM. In the sole clinical trial where DBBM was used as carrier for non-glycosylated 
rhBMP-2 the results show that overall  bone formation was not increased compared 
to DBBM alone but maturation of bone as well as direct coverage of DBBM by bone 
had advanced significantly [32]. Both results suggest that non-glycosylated rhBMP-2 
delivered by DBBM is still active but the long range effect is limited due to the high 
affinity of rhBMP-2 to DBBM. Whether this remaining activity is due to the low 
amount of rhBMP-2 dissolved in the extracellular matrix, rhBMP-2 resolubilized after 
the slow dissolution of DBBM in vivo or rhBMP-2 adsorbed to DBBM cannot be 
determined based on these results. 
Combining the two previously discussed materials we Incorporated rhBMP-2 into 
mPEG hydrogels together with DBBM. This led to a constantly low concentration of 
rhBMP-2 in the cell culture medium supernatant during the 15 days of incubation, 
with a small increase after three days. After 15 days, in contrast to the samples with 
DBBM alone, a significantly higher concentration of glycosylated compared to non-
glycosylated rhBMP-2 can be detected 
(
 
Figure 4 A). This result is confirmed by cell culture experiments that show the same 
significant difference for the amount of active rhBMP-2 detectable in the cell culture 
medium supernatant (                      
 
Figure 8). We attribute this to the reduced detectability of non-glycosylated rhBMP-2 
if present during formation of mPEG hydrogels (                     
 
Figure 2). Control samples for DBBM in mPEG hydrogels initially only show a small 
decrease in rhBMP-2 concentration in the cell culture medium supernatant. 
However, the concentration drops drastically after three days 
(
 
Figure 4 B). This drop can be explained with the hydrolyzation of the mPEG hydrogel 
that was covering the DBBM, leading to an adsorption of rhBMP-2 to DBBM. The 
concentration of non-glycosylated rhBMP-2 is, in agreement with the results for 
DBBM alone, significantly higher than for glycosylated rhBMP-2, supporting the 
assumption that the only reason for the lower concentration of non-glycosylated 
rhBMP-2 in the samples is due to its interaction with the mPEG hydrogel 
components during hydrogel formation. 
5 Conclusions 
We have shown that mPEG hydrogels interact with rhBMP-2 and reduce its activity. 
Furthermore, we found a strong affinity of rhBMP-2 to DBBM. Based on these results 
we question the use of mPEG hydrogels as a carrier-system for rhBMP-2 in 
conjunction with DBBM, since the use of DBBM with preadsorbed rhBMP-2 alone 
yields a higher BMP activity, which might translate to better results in vivo. Since the 
affinity of non-glycosylated rhBMP-2 to DBBM is lower than the affinity of the 
glycosylated variant, non-glycosylated rhBMP-2 may be used if an initial high 
concentration of rhBMP-2 is desired to attract cells chemotactically. Further research 
on this aspect is necessary to determine if rhBMP-2 adsorbed to DBBM and 
hydroxyapatite in general is active or denatured and/or released in an active form 
during degradation. However if other needs, e.g. formability or stability of the bone 
substitute require  the use of mPEG hydrogels, glycosylated rhBMP-2 is the 
preferred growth factor since its interactions with mPEG hydrogels is significantly 
lower compared to non-glycosylated rhBMP-2.  
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6 Figures 
      
Figure 1: Scheme of experimental setups. Glycosylated and non-glycosylated 
rhBMP-2 was incorporated into mPEG hydrogels, adsorbed to DBBM and 
incorporated into an mPEG hydrogel together with DBBM. These samples were 
immersed in cell culture medium to investigate concentration and activity in the 
supernatant over time. In order to separate effects derived from the adsorption or 
incorporation procedures, controls devoid of rhBMP-2 were prepared and immersed 
in cell culture medium that was subsequently supplemented with rhBMP-2. Empty 
controls without rhBMP-2 were prepared in order to evaluate the effect of the bone 
substitute material degradation products on cell viability. The low biological half-life 
of rhBMP-2 was taken into account by comparing all results to a positive control of 
rhBMP-2 in cell culture medium. 
                      
Figure 2. Concentration of glycosylated and non-glycosylated rhBMP-2 in the cell 
culture medium supernatant of mPEG samples detected by an ELISA.  
 Figure 3. Concentration of glycosylated and non-glycosylated rhBMP-2 in the cell 
culture medium supernatant of DBBM samples and controls detected by an ELISA. 
A) DBBM samples. B) DBBM controls.  
 Figure 4. Concentration of glycosylated and non-glycosylated rhBMP-2 in the cell 
culture medium supernatant of DBBM in mPEG samples and controls detected by an 
ELISA. A) DBBM in mPEG samples B) DBBM in mPEG controls. 
 Figure 5: Cell viability of C2C12 cells stimulated with cell culture medium 
supernatant from mPEG, DBBM and DBBM in mPEG measured by cell proliferation 
reagent WST-1. A) After 3 days of stimulation. B) After 6 days of stimulation. An 
asterisk indicates a significant difference between samples (p<0.05) 
  
Figure 6: DNA concentration per sample of cells stimulated with cell culture medium 
supernatant from mPEG, DBBM and DBBM in mPEG hydrogel samples determined 
by a PicoGreen assay. An asterisk indicates a significant difference between 
samples (p<0.05) 
 Figure 7: Bioactivity and stability of non-glycosylated and glycosylated rhBMP-2. A) 
ALP activity of cells stimulated by various concentrations of non-glycosylated and 
glycosylated rhBMP-2. B) ALP activity of cells stimulated with rhBMP-2 preincubated 
for various time spans at 37 °C in cell culture medium.  
                             
Figure 8: Bioactivity of glycosylated and non-glycosylated rhBMP-2 in the cell culture 
medium supernatant of mPEG, DBBM and DBBM in mPEG samples after 15 days of 
incubation. C2C12 cells were stimulated with cell culture medium supernatant from 
the samples and incubated for 6 days followed by an ALP activity assay.  
